Skip to content

Conventional Photodynamic Therapy Versus Daylight Photodynamic Therapy for The Treatment of Acne Vulgaris

A Split-Face Clinical Trial of Conventional Photodynamic Therapy Versus Daylight Photodynamic Therapy for The Treatment of Acne Vulgaris

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04631250
Enrollment
15
Registered
2020-11-17
Start date
2018-11-01
Completion date
2020-07-01
Last updated
2020-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Keywords

acne vulgaris, photodynamic therapy, PDT, Daylight PDT

Brief summary

Photodynamic therapy (PDT) is considered an effective treatment for acne vulgaris. The study aims to determine whether treatment with daylight as an illumination source is as effective as conventional, red light illumination. 15 patients with acne vulgaris received 4 treatment sessions at three-week intervals. First, 5-aminolevulinic acid (ALA) was applied to the entire face. Then the face was divided into two symmetrical contralateral treatment areas: the left was covered with a light-impermeable dressing, while the right face was exposed to sunlight. After 2 hours outdoors, the right side of the face was covered, and the left half was illuminated with red light.

Detailed description

Photodynamic therapy (PDT) is considered an effective treatment for acne vulgaris .One of the most important drawbacks of PDT is the pain during illumination. It has been shown that daylight PDT is an effective treatment for actinic keratosis. In order to examine the efficacy of daylight PDT for acne vulgaris, we used a split-face design: the face was divided into two symmetrical contralateral treatment areas: the left was covered with a light-impermeable dressing, while the right face was exposed to daylight. After 2 hours outdoors, the right side of the face was covered, and the left half was illuminated with red light.

Interventions

DRUG5-Aminolevulinic Acid-Containing Product in Cutaneous Dose Form

5-Aminolevulinic Acid was applied to both sides of the face.

Sponsors

Tel-Aviv Sourasky Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

The photographs of the patients were evaluated by two dermatologists blinded to the study protocol.

Intervention model description

Split Face design is a common model used in dermatology to study the difference between two treatments on a facial condition. The face was divided into two symmetrical contralateral treatment areas: the left was covered with a light-impermeable dressing, while the right face was exposed to sunlight. After 2 hours outdoors, the right side of the face was covered, and the left half was illuminated with red light.

Eligibility

Sex/Gender
ALL
Age
14 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients with a clinical diagnosis of acne vulgaris on the face * Acne lesions include inflammatory papules/ pustules/ nodules and cysts , and non-inflammatory open and closed comedones. * Acne refractory to conventional therapies * Patients who are unable or do not want to take oral isotretinoin * Patients who cannot tolerate isotretinoin

Exclusion criteria

* History of oral retinoid use within 12 months of study entry * Systemic antibiotics within 6 month of study entry * Topical acne treatment within 1 month of study entry * Presence of any other skin disease that could interfere with the assessment of the acne, such as folliculitis or rosacea * Presence of any other systemic disease that could affect the acne severity by its presence, such as polycystic ovarian syndrome, or by any medication prescribed for the treatment of the systemic diseases (retinoids, antibiotics). * Pregnancy or intention to get pregnant * lactating woman * Porphyria * Photosensitive dermatoses * Allergy to any component of the photosensitizer compound * Personal history of melanoma or dysplastic nevi * A beard or other facial hair that might interfere with study assessments;

Design outcomes

Primary

MeasureTime frameDescription
Reduction in acne lesion counts and total acne severity score on both sides of the faceWe measured the difference between the number of lesions in the first visit and the number of lesions in the follow up visit, 12 weeks after the last teatmentChange in the number of inflammatory and non-inflammatory acne lesions
Difference in adverse effects between the two sidesAfter each of the 4 treatment sessionsDifference in pain scores, erythema after each treatment, erosions and pustulosis

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026